致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- ...

智通财经APP讯，微创机器人-B(02252)发布公告，近日公司接获中国证券监督管理委员会就其申请H股 全流通发出的正式备案通知书，据此，公司已完成有关公司两名股东持有的合共598.98万股非上市股份 按一比一的基准转换为598.98万股H股的中国证监会备案。该等598.98万股H股将于完成有关转换及联交 所授出上市批准后于联交所主板上市及买卖。通知自中国证监会批准之日起12个月内有效。 ...

微创机器人-B(02252)发布公告，近日公司接获中国证券监督管理委员会就其申请H股全流通发出的正式 备案通知书，据此，公司已完成有关公司两名股东持有的合共598.98万股非上市股份按一比一的基准转 换为598.98万股H股的中国证监会备案。该等598.98万股H股将于完成有关转换及联交所授出上市批准后 于联交所主板上市及买卖。通知自中国证监会批准之日起12个月内有效。 ...

格隆汇2月4日丨微创机器人-B(02252.HK)宣布，近日公司接获中国证券监督管理委员会就其申请H股全 流通发出的正式备案通知书，据此，公司已完成有关公司两名股东持有的合共5,989,798股非上市股份按 一比一的基准转换为5,989,798股H股的中国证监会备案。该等5,989,798股H股将于完成有关转换及联交 所授出上市批准後于联交所主板上市及买卖。通知自中国证监会批准之日起12个月内有效。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） – 1 – | | | 於本公告日期 | | --- | --- | --- | | | | 佔本公司 | | | 將轉換為 | 已發行股本 | | | H股的非上市 | 總額的概約 | | 股東姓名 | 股份數目 | 附註 百分比 | | 上海潤昆天祿企業管理中心（有限合夥） | 589,806 | 0.0572% | | 深圳芯龍投資合夥企業（有限合夥） | 5,399,992 | 0.5236% | | 總計 | 5,989,798 | 0.5808% | 附註： 於本公告日期，本公司已發行合共1,031,330,331股股份，包括6,599,543股非上市股份及 1,024,730,788股H股。 於本公告日期，本公司有 ...

Core Viewpoint - The orthopedic surgical robot company Tianzhihang has released a performance forecast, expecting revenue of 270 million to 300 million yuan in 2025, representing a year-on-year growth of 50.97% to 67.75% [1] - The industry is witnessing significant growth, with competitors like MicroPort Robotics also projecting substantial revenue increases, indicating a competitive landscape in the surgical robotics market [1][8] Industry Overview - Surgical robots are considered a "gem" in the high-end medical device sector, with laparoscopic and orthopedic surgical robots being the most mature and largest segments [1] - The domestic sales figures for these segments from January to November 2025 are projected to be 1.823 billion yuan and 654 million yuan, respectively, with sales of 119 and 86 units [1] Market Dynamics - The penetration rates for robot-assisted laparoscopic surgeries in China and the U.S. are 0.7% and 21.9%, respectively, indicating significant room for growth in the domestic market [2] - High prices, often exceeding millions, are a major barrier to the widespread adoption of surgical robots [3] Competitive Landscape - The market is becoming increasingly competitive, with more products receiving approval and entering clinical applications, leading to aggressive pricing strategies among manufacturers [3][5] - The number of approved laparoscopic surgical robots in China is expected to reach 13 by the end of 2025, with major players like United Imaging entering the market [3] Pricing and Policy Changes - The National Healthcare Security Administration has introduced a unified pricing guideline for surgical robots, which will help clarify costs for hospitals and encourage adoption [10][13] - The pricing structure will be linked to the level of participation and clinical value provided by the surgical robots, promoting their use in complex surgeries [12][13] International Expansion - Leading companies are actively exploring overseas markets to enhance their performance, with MicroPort Robotics reporting significant growth in international sales [8] - The challenges of international expansion include varying regulatory requirements and the need for localized service and support systems [9] Future Outlook - The domestic market for surgical robots is expected to see increased competition and potential price adjustments in the coming years, particularly for laparoscopic robots [5] - The overall market environment is improving, with a rise in bidding opportunities for orthopedic surgical robots, contributing to revenue growth for companies like Tianzhihang [9]

Group 1 - The performance of the robotics sector is mixed, with companies like Woan Robotics (06600) rising by 18.71%, Gangzi Robotics (00370) by 4.44%, and Ubtech (09880) by 2.34%, while others like Yunji (02670) fell by 3.17% and Micron Robotics (02252) by 1.62% [1][2] - Tencent's Senior Executive Vice President, Tang Daosheng, stated that Chinese robotics companies deserve higher valuations in the capital market, emphasizing that the competitive environment forces companies to accelerate technology iteration and application, which has not been fully priced by the market [1][2] - Guojin Securities highlighted that 2026 is a crucial year for humanoid robots, with Tesla's supply chain expected to launch its first mass-produced product in Q1 2026, and large-scale production lines to be completed in H1 2026, leading to a significant increase in domestic shipments from thousands to tens of thousands [1][2]

Core Insights - The article highlights that the Chinese surgical robot market is transitioning from an early development phase to a rapid growth phase, driven by the implementation of the medical insurance bureau's pricing policy and accelerated overseas market expansion [1][3]. Market Size and Growth - The Chinese surgical robot market is projected to grow from approximately 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, representing a compound annual growth rate (CAGR) of about 34% [2][5]. - In comparison, the global market is expected to increase from 21.2 billion USD to 75 billion USD during the same period, with a CAGR of around 17%, indicating that China's growth rate significantly outpaces the global average [2]. Market Segmentation - Laparoscopic surgical robots are expected to dominate the market, accounting for 58% of the total market size in 2024, with a projected CAGR of 29% from 2024 to 2032, reaching 32.1 billion RMB by 2032 [5]. - The orthopedic surgical robot market follows closely, with a market share of 26% in installed capacity and 22% in sales revenue. The CAGR for this segment is anticipated to be 41%, reaching 21.3 billion RMB by 2032 [5]. Policy Impact - The year 2026 is identified as a critical turning point due to the establishment of a national pricing framework, which will address the economic concerns of hospitals regarding the adoption of surgical robots [7][9]. - The medical insurance bureau's guidelines released on January 20, 2026, categorize surgical robots into four types and provide a clear reimbursement structure, which is expected to facilitate product adoption in hospitals [9]. International Expansion - The article notes that the Chinese surgical robot market currently accounts for only about 5% of the global market, indicating significant potential for overseas expansion [10]. - Leading domestic companies are rapidly entering international markets, with notable achievements such as MicroPort's 160 global commercial orders and the increasing share of overseas revenue for companies like Precision Medical [10]. Business Model - The surgical robot business model is likened to the "razor and blades" model, where the primary revenue source comes from consumables and services rather than just equipment sales [11][12]. - Companies are encouraged to focus on increasing installed base as a key indicator for future cash flow, with the potential for high-value orthopedic consumables sales being a critical factor for profitability [12].

摩通将微创机器人2025财年的销售预测下调12%，但对今明两年的预测上调3%至4%。该行仍然相信公 司为全球手术机械人领域中强大的中国竞争者，并预期其将继续在海外(特别是欧洲、拉丁美洲、亚太 等地区)持续增长；同时认为，该股的下一个催化剂将是潜在的累计订单公布及其盈利表现。 摩根大通发布研报称，微创机器人-B(02252)初步2025财年业绩预测高于市场预期，但较该行预估为 低，将其目标价从42港元微调至41港元，评级"增持"，仍为该行于中国医疗科技行业的首选。 摩通续指，根据微创机器人的初步2025财年业绩，因Skywalker销售低于预期，将集团去年销售预测从 6.46亿元人民币(下同)下调至5.67亿元，不过继续预期公司将在今年达到盈亏平衡，对其今年销售预测 由原来的13.56亿元，上调至14.16亿元。 ...

摩通续指，根据微创机器人的初步2025财年业绩，因Skywalker销售低于预期，将集团去年销售预测从 6.46亿元人民币(下同)下调至5.67亿元，不过继续预期公司将在今年达到盈亏平衡，对其今年销售预测 由原来的13.56亿元，上调至14.16亿元。 智通财经APP获悉，摩根大通发布研报称，微创机器人-B(02252)初步2025财年业绩预测高于市场预期， 但较该行预估为低，将其目标价从42港元微调至41港元，评级"增持"，仍为该行于中国医疗科技行业的 首选。 摩通将微创机器人2025财年的销售预测下调12%，但对今明两年的预测上调3%至4%。该行仍然相信公 司为全球手术机械人领域中强大的中国竞争者，并预期其将继续在海外(特别是欧洲、拉丁美洲、亚太 等地区)持续增长；同时认为，该股的下一个催化剂将是潜在的累计订单公布及其盈利表现。 ...